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Abstract Background and Aim:Neutropenia is a serious adverse event for patients who
are treated with cetuximab, an inhibitor of endothelial growth factor re-
ceptor. However, there is no consistent result of the relationship between
cetuximab and neutropenia in randomized controlled trials (RCTs). We did a
systematic review and meta-analysis of published RCTs to assess the overall
risk of neutropenia associated with cetuximab.
Methods: PubMed, Cochrane Central Register of Controlled Trials, EMBASE,
and American Society of Clinical Oncology conferences were searched for rel-
evant RCTs. Quantitative and qualitative analyses were carried out to evaluate
the association between neutropenia and cetuximab. Both the fixed-effect model
and random-effects model were used.
Results:A total of 7186 patients with a variety of advanced cancers from 14 trials
were included in our analysis. The overall incidence of neutropenia in patients
receiving cetuximab was 33% (95% CI 26, 43). Patients treated with cetuximab
had a significantly increased risk of neutropenia compared with patients treated
with control medication, with a relative risk (RR) of 1.12 (95% CI 1.05, 1.19;
fixed-effect model). Risk varied with tumor type. Higher risks were observed in
patients with colorectal carcinoma (RR 1.17; 95% CI 1.04, 1.32; fixed-effect
model) and non-small cell lung cancer (RR 1.07; 95% CI 0.99, 1.16; fixed-effect
model).
Conclusion: Cetuximab is associated with a significant risk of neutropenia in
patients with advanced cancer receiving concurrent chemotherapy.
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Introduction
The endothelial growth factor receptor (EGFR),
presented in many cell types, is a transmembrane
protein consisting of an extracellular binding do-
main, a hydrophobic transmembrane segment, and
a cytoplasmic tyrosine kinase domain, and it can be
considered as one of the best characterized ligand-
receptor systems.[1] The overexpression of EGFR
has been found in a variety of solid tumors[2] and
endothelial growth factor (EGF) has played a cru-
cial role in disease progression, poor prognosis, and
reduced sensitivity to chemotherapy.[3] Therefore
blocking the signaling of EGF has been a major
focus of new cancer therapeutics.
Cetuximab is a human-murine monoclonal an-
tibody directed against EGFR protein, which is
expressed on the surface of human tumor cells.[4] It
was approved by the US FDA for use in metastatic
colorectal cancer in February 2004,[5] and first
gained approval in Europe for use in the treatment
of EGFR-expressing metastatic colorectal cancer
following failure of irinotecan-containing regi-
mens.[6] More recently, a meta-analysis demon-
strated an improved overall survival in non-small
cell lung cancer patients receiving chemotherapy
plus cetuximab compared with chemotherapy
alone.[7] The clinical efficacy of cetuximab in many
other malignancies, such as head and neck cancer
and pancreatic cancer, is also currently undergoing
extensive evaluation.
With the use of cetuximab, substantial adverse
events have been observed. Rash, diarrhea, fatigue,
neutropenia, hypertension, nausea, infusion-related
or hypersensitivity reactions, and hand-foot skin
reactions were very common when cetuximab was
administrated for advanced cancer.[8] In addition,
recently, a new adverse event (posterior reversible
leukoencephalopathy), which is potentially life-
threatening, has been found. Reversible posterior
leukoencephalopathy syndrome, of which clinical
symptoms include headache, decreased alertness,
and mental abnormalities, is a disorder with typical
radiologic findings in the posterior regions of the
cerebral hemisphere and cerebellum.[9] Neutropenia
is the most common dose-limiting toxicity of mye-
losuppressive chemotherapy and has been found in
51% of patients who were treated for lymphoma or
solid tissue malignancy.[10] Neutropenia also puts
patients at high risk of infection, which can be life-
threatening.[11] However, there is no consistent
result of the relationship between cetuximab
and neutropenia in randomized controlled trials
(RCTs). For example, significant association be-
tween cetuximab and neutropenia has been estab-
lished in the studies reported by Burtness et al.[12]
and Rosell et al.,[13] while Bokemeyer et al.[14] and
Borner et al.[15] reported that there was no signif-
icant association between cetuximab and neutro-
penia. Thus, we undertook a systematic review
of the relevant RCTs to evaluate the risk of neu-




An extensive search of PubMed (fromMay 1996
to March 2011), Cochrane Central Register of
Controlled Trials (from Cochrane Library Issue 1,
2001 to Cochrane Library Issue 3, 2011), and
EMBASE (fromOctober 1997 toMarch 2011) was
performed to identify relevant RCTs for our meta-
analysis (the detailed search strategy can be found
in the supplemental digital content, http://links.
adisonline.com/DRZ/A5). Abstracts and virtual
meeting presentations from the American Society
of Clinical Oncology conferences held between
January 2000 and March 2011 were also searched
for relevant RCTs. We also searched the reference
lists of articles, reviews, letters to the editor, and
case reports to find those not yet included in the
computerized databases. The language of the re-
search papers was not restricted.
Study Selection
RCTs that directly compared advanced cancer
patients treated with and without cetuximab, re-
spectively, were selected for our analysis. Phase I
and single-arm phase II trials were excluded due
to the lack of control groups. Specifically, clinical
trials that met the following criteria were included
in the meta-analysis: (i) prospective phase II
and phase III RCTs in patients with advanced
cancer; (ii) random assignment of participants to
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cetuximab treatment or control group (placebo
or best supportive care) in addition to concurrent
chemotherapy and/or treatment with a biological
agent; and (iii) available data, including events or
incidences of neutropenia and sample size for
analysis.
Data Extraction
Two researchers (LW and YC) extracted data
from each identified trial independently in a pre-
designed review form. The following data were in-
cluded: authors of each study, publication year,
trial design, number of patients, number of patients
eligible for neutropenia evaluation, age, sex, inter-
vention, dose of cetuximab administered, cancer
type, phase of trial, follow-up time, allocation con-
cealment, blinded analysis, and events or incidences
of grade 3 or 4 neutropenia.
Qualitative Assessment
The studies were appraised independently by
two authors (LW and YC) based on the standard
criteria (randomization, blinding, loss to follow-
up, and generation of allocation concealment),
and additional quantitative quality was assessed
using the scoring system developed by Jaded
et al.,[16] appropriately modified according to the
treatments under study. The quality scoring system
was as follows: (i) adequacy of randomization –
appropriate with detailed description of random-
ization (score 2), randomized but details not
reported (score 1), inappropriate randomization
(score 0); (ii) allocation concealment – properly
used (score 2), unclear (score 1), not used (score
0); (iii) blinded method – double blind (score 2),
single-blind (score 1), and open-label or unclear
(score 0); and (iv) drop-outs and follow-ups – data
given (score 1), and data not given (score 0). Any
disagreement was resolved by discussion.
Clinical Endpoints
The primary endpoint was the incidence of
neutropenia. Neutropenia in these studies were
assessed and recorded according to Common
Terminology Criteria for Adverse Events (version
2 or 3).[17,18] For this study, severe neutropenia
was defined as grade 3 or above neutropenia.
Statistical Analysis
Stata v10.0 software (StataCorp, College Sta-
tion, TX, USA) was used for statistical analysis.
We calculated the incidence of neutropenia by
using the number of patients with neutropenia in
the cetuximab group and total number of patients
receiving cetuximab treatment. The proportion
of patients with neutropenia was calculated and
the 95% confidence interval was derived for each
trial. Relative risk (RR) is the ratio of the risk of
an event in the two groups. Odds ratio is the ratio
of the odds of an event. Difference in means is
a standard statistic that measures the absolute
difference between the mean values in the two
groups in a clinical trial. RR is applicable to all
kinds of data, while odds ratio is only applicable
to events of small incidence; thus, the RR was
adopted. A subgroup analysis according to tu-
mor type was performed.
We used the chi-square test of heterogeneity
and the I2 measure of inconsistency to assess the
heterogeneity between trials. With an I2 value
larger than 50% indicating significant hetero-
geneity, the following techniques were used to
explain it: (i) subgroup analysis; (ii) sensitivity
analysis performed by excluding the trials that
potentially biased the results; and (iii) the random-
effects model was used after efforts were made to
explore the cause of the heterogeneity. The Begg’s
test was used to determine the presence of pub-
lication bias regarding our primary variable (RR
of neutropenia). A two-tailed p-value of <0.05 was
considered statistically significant.
Results
A total of 155 clinical studies relevant to ce-
tuximab were identified by our literature search.
Review articles, case reports, meta-analyses,
observational studies (n = 48), phase I studies
(n= 14), single-arm phase II studies (n= 20), dupli-
cates (n= 16), studies in which both control and
treatment groups received cetuximab (n= 28), and
those data not adequate for assessment of severe
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neutropenia (n= 15) [figure 1] were excluded. Ulti-
mately, 14 RCTs, including six phase II and eight
phase III studies, were selected for analysis, in-
volving 7186 patients. The main characteristics
(type of study design, underlying malignancy of
included patients, concurrent treatment, number of
patients, and follow-up time) of the 14 included
RCTs are presented in table I. Randomized treat-
ment allocation sequences were generated in all
trials. Only one trial was double-blinded and
placebo-controlled,[12] two other trials were single-
blinded,[15,28] nine of the trials were open-
label,[13,14,20-24,26,27] and the two remaining trials
were not specified.[19,25] All trials reported the
number and reason of withdrawals and drop-outs.
None of the trials mentioned allocation conceal-
ment. Thirteen trials were described as multicenter
trials, and one did not mention it.[19] The median
follow-up time for 13 studies[12-15,20-28] ranged from
8 to 32 months, with one not mentioned. Neutro-
penia was assessed and recorded according to
the National Cancer Institute’s common toxicity
criteria version 2 or 3.[17,18] The baseline Eastern
Cooperative Oncology Group (ECOG) perfor-
mance status of most patients was between 0 and 2.
Only one patient’s ECOG performance status was
3.[20] Patients were required to have adequate he-
patic, renal, and hematologic function. Underlying
malignancies were colorectal cancer (five studies),
non-small cell lung cancer (four studies), pancreatic
cancer (two studies), head and neck cancer (two
studies), and squamous cell carcinoma of the
esophagus (one study).
Both the fixed-effect and random-effects models
were used (I2= 40.7%; p= 0.057). The overall RRs
of severe neutropenia with cetuximab versus con-
trol were 1.12 (95% CI 1.05, 1.19; p= 0.001; fixed-
effect model [figure 2]) and 1.14 (95%CI 1.03, 1.25;
p= 0.001; random-effects model), indicating signif-
icantly higher incidence of neutropenia in cetuximab
groups. The RRs of subgroup analysis suggested
a significant association between severe neutro-
penia and cetuximab treatment among patients
with colorectal cancer (RR 1.17; 95% CI 1.04,
1.32; fixed-effect model [figure 2]: and RR 1.16;
95% CI 1.00, 1.34; random-effects model). Nu-
merically increased incidence associated with ce-
tuximab was found in patients with non-small cell
lung cancer, with RRs of 1.07 (95% CI 0.99, 1.16;
fixed-effect model) and 1.11 (95% CI 0.97, 1.28;
Potentially relevant studies identified from search strategy (n = 155)
Publication retrieved for detailed
evaluation (n = 77)
RCTs included in final analysis
(n = 14)
Articles excluded (n = 78):
   not RCTs (n = 48)
   phase I trials (n = 14)
   duplicates (n = 16)
Articles excluded (n = 63):
   single arm phase II trials (n = 20)
   both control and treatment groups
   received cetuximab (n = 28)
   data not adequate for assessment 
   of neutropenia (n = 15)
Potentially relevant studies identified
through database searching (n = 130)
Potentially relevant studies identified
through other sources (n = 25)
Fig. 1. Selection process for RCTs included in the meta-analysis. RCT = randomized controlled trial.
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random-effects model), but no statistical differ-
ence was found. The RRs of severe neutropenia
were lowest in patients with pancreatic cancer
treated with cetuximab compared with controls
(RR 1.02; 95% CI 0.79, 1.31; fixed-effect model:
and RR 1.06; 95% CI 0.72, 1.55; random-effects
model), and highest in patients with squamous
cell carcinoma of the esophagus (RR 1.64; 95%
CI 0.53, 5.04; fixed-effect model: and RR 1.64;
95% CI 0.53, 5.04; random-effects model). Nine
of 14 trials reported that the cetuximab groups
had a higher incidence of severe neutropenia
compared with the control groups, while four
trials showed lower and one trial equal incidences
of severe neutropenia (figure 3).
The overall incidence of severe neutropenia in
patients receiving cetuximab was 33% (95% CI
26, 43). Patients with different tumors might be at
different risks of severe neutropenia due to dif-
ferences in tumor malignancy and associated
treatment. We explored whether having a specific
type of cancer is associated with a higher risk of
severe neutropenia compared with other cancers.
As shown in table II, the risk of severe neutro-
penia varied according to tumor type. The high-
est incidence of severe neutropenia was found in




















Philip et al.[19] III 743 716 Pancreatic cancer Gemcitabine 3 250 27
















Van Cutsem et al.[23] III 1202 1202 Colorectal cancer Leucovorin and
fluorouracil
3 250 16
















Sobrero et al.[26] III 1298 1267 Colorectal cancer Irinotecan 3 250 32
Borner et al.[15] II 74 74 Colorectal cancer Capecitabine and
oxaliplatin
4 250 16





Cascinu et al.[28] II 84 84 Pancreatic cancer Gemcitabine and
cisplatin
5 250 16










NA= data not available.
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patients with non-small cell lung cancer (61%;
95% CI 50, 74), while the lowest incidence was
seen in patients with squamous cell carcinoma of
the esophagus (22%; 95% CI 11, 45).
No publication bias was detected for the pri-
mary variable of this study (RR of severe neu-
tropenia) by the Begg’s or Egger’s tests (Begg’s
test, p = 0.38; Egger’s test, p = 0.29). As shown in
figure 4, the shapes of the funnel plots appeared
symmetrical in all comparisons, indicating the
absence of publication bias.
Discussion
Caner patients have an increased susceptibility
to severe infections, especially when receiving
chemotherapy. Bodey et al.[29] reported that the
most important factor contributing to the in-
creasing infection risk is an absolute neutrophil
count of <0.5 · 109/L. In the RCTs discussing
the association of neutropenia and cetuximab,
an individual RCT is not powered to detect a
significant relationship, so the contribution of
Cetuximab Control
total events RR (95% CI)
1.15 (0.95, 1.38) 13.89
1.40 (0.88, 2.22) 2.51
1.28 (1.07, 1.53) 14.30
0.33 (0.01, 7.93) 0.14
1.17 (1.04, 1.32) 36.23
1.10 (0.97, 1.26) 16.77
1.03 (0.92, 1.15) 26.83
1.00 (0.70, 1.42) 2.96
1.56 (1.14, 2.12) 2.14
1.07 (0.99, 1.16) 48.70
0.97 (0.75, 1.26) 8.06
1.67 (0.67, 4.17) 0.56
1.02 (0.79, 1.31) 8.62
0.96 (0.68, 1.36) 4.74
2.14 (1.27, 3.60) 1.32
1.22 (0.92, 1.62) 6.06
1.64 (0.53, 5.04) 0.39
1.64 (0.53, 5.04) 0.39
1.12 (1.05, 1.19) 100.00

















































Subtotal (I2 24.2%; p = 0.260)
Subtotal (I2 18.6%; p = 0.268)
Subtotal (I2 84.2%; p = 0.012)
Subtotal
Overall (I2 40.7%; p = 0.057)
Advanced pancreatic cancer
Recurrent head and neck cancer
Metastatic squamous cell carcinoma of the esophagus
events



















Subtotal (I2 53.8%; p = 0.090)
Advanced non-small-cell lung cancer
Fig. 2. Relative risk (RR) of neutropenia associated with cetuximab treatment compared with control treatment. An RR <1 means a
numerically lower incidence than control chemotherapy and an RR >1 means a numerically higher incidence than control chemotherapy.
If the lower value of the 95% CI range is greater than 1, it means that there is a statistically significant difference between the two groups.
Conversely, a value of 1 or smaller indicates non-significance.
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cetuximab to the development of neutropenia is
difficult to assess in one RCT. Thus, we com-
bined 14 RCTs to overcome this limitation. The
result showed a high incidence of severe neutro-
penia (33%; 95% CI 26, 43) associated with
cetuximab treatment for advanced cancer. Ce-
tuximab treatment had a higher risk of severe
neutropenia compared with control (RR 1.12;
95% CI 1.05, 1.19).
Multiple distinctmechanisms could be involved
in the pathogenesis of the severe cetuximab-
associated neutropenia. The relationship between
cetuximab and neutropenia might be related
to a direct myelosuppression. EGF and the
EGF-like protein family play an important role
both in physiologic processes, such as cell prolif-
eration and differentiation, and wound heal-
ing.[30-32] Cetuximab, which targets EGFR,might
inhibit the proliferation of neutrophil through
blocking the singling pathway of EGFR. Further-
more, it has been described that EGF enhances tu-
mor necrosis factor (TNF)-a-induced activation in
human neutrophils,[33] and TNFa is an important
inflammatory mediator to activate neutrophils.
This study also showed that the risk of severe
neutropenia with cetuximab can vary with tumor
type. The riskwas significantly increased in patients
with advanced colorectal cancer who received ce-
tuximab. Therefore, more attention should be paid
to patients with advanced colorectal cancer when
cetuximab-based therapy is used. Patients with ad-
vanced non-small cell lung cancer had the highest
incidence of severe neutropenia, although there was
no significant difference comparing cetuximab-
based therapy with control treatment. Cetuximab-
based therapy had a tendency to significantly
increase the incidence of severe neutropenia when
given to patients with advanced non-small cell lung
cancer. One of the reasons that non-small cell lung
cancer patients had the highest incidence of severe
neutropenia might be that current chemotherapies
used for non-small cell lung cancer patients have
the most serious myelosuppression. Another rea-
son may be the complicated nature of non-small
cell lung cancer.
Several limitations of our analysis are worth
considering. Firstly, with every meta-analysis,
results are affected by the clinical heterogeneity.
These trials have different patient clinical profiles,
concurrent chemotherapies, lengths of follow-up,







Fig. 3. Comparison of incidence between cetuximab groups and
control groups. 64% of all included trials reported patients treated
with cetuximab had a numerically higher incidence of neutropenia,
while 29% were lower, and 7% were equal.
Table II. Incidence of neutropenia with cetuximab among patients with various tumor types
Tumor type No. of studies No. of cetuximab events
(sample size)




Overall 14 1177 (3451) 1077 (3735) 0.33 (0.26, 0.43)
Colorectal cancer 5 444 (1723) 397 (1993) 0.23 (0.17, 0.31)
Non-small cell lung cancer 4 553 (1003) 521 (1015) 0.61 (0.50, 0.74)
Pancreatic cancer 2 94 (413) 91 (414) 0.23 (0.19, 0.28)
Head and neck cancer 2 79 (279) 64 (280) 0.34 (0.15, 0.77)
Squamous cell carcinoma of the esophagus 1 7 (33) 4 (33) 0.22 (0.11, 0.45)
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are inevitable, and there is always some hetero-
geneity, even within individual trials. However,
heterogeneity does not necessarily preclude pooling
of the results because individual patients are only
directly compared with other patients within the
same trial and not across the trials.[34,35] Given this
uncertainty resulting from clinical heterogeneity, we
performed subgroup analysis in our meta-analysis.
Secondly, ourmeta-analysis only included 14 studies
of 155 identified in our research. In this regard, we
selected only those trials conducted with a rigorous
methodology in order to provide solid conclusions.
Indeed, meta-analyses often include small numbers
of studies, and heterogeneity is therefore a nec-
essary consequence. Higgins et al.[36] evaluated
39 Cochrane reviews and found that 67% of them
included five studies and 20% included ten stud-
ies. A lower threshold for the number of studies
to be included in a meta-analysis has not yet been
established.
As almost all the studies included in this anal-
ysis used the same doses of cetuximab, future
studies are recommended to investigate whether
a higher dose of cetuximab has higher risk of
neutropenia. The risk of neutropenia was sig-
nificantly increased in patients with advanced
colorectal cancer who received cetuximab, there-
fore, it is important to explore how to prevent
neutropenia in advanced colorectal cancer
patients. Patients with advanced non-small cell
lung cancer had the highest incidence of severe
neutropenia, although there was no significant
difference comparing cetuximab-based therapy
with control treatment, so more studies are
needed to find out the reason why patients with
advanced non-small cell lung cancer had the
highest incidence of severe neutropenia. More
RCTs that include the first-line drugs with or
without cetuximab are recommended.
In conclusion, our data have shown that ce-
tuximab is associated with a significant risk of
neutropenia in patients with advanced cancer re-
ceiving concurrent chemotherapy. The risk varies
with tumor type and a higher risk is seen in
patients with colorectal cancer and non-small cell
lung cancer. Early monitoring and effective treat-
ment of neutropenia is important for patients who
receive cetuximab-based therapy.
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